Bristol-Myers Squibb Awards Immunicon Research Services Agreement for Oncology Biomarker Development

Immunicon Corporation has announced that the Company entered into a Research Services Agreement with Bristol-Myers Squibb (BMS) involving protein and molecular targets associated with circulating tumor cells (CTCs).

Leon Terstappen, MD, PhD, Chief Scientific Officer of Immunicon commented, “The list of pharmaceutical partners and biomarkers continues to expand. Our collaborations span across protein biomarkers, phosphoproteins and a variety of FISH assays to study gene amplification in a number of different carcinomas. We believe that our development work will advance the understanding of cancer biology as well as accelerate the time to market for promising new drugs.”